JP2003506414A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003506414A5 JP2003506414A5 JP2001514977A JP2001514977A JP2003506414A5 JP 2003506414 A5 JP2003506414 A5 JP 2003506414A5 JP 2001514977 A JP2001514977 A JP 2001514977A JP 2001514977 A JP2001514977 A JP 2001514977A JP 2003506414 A5 JP2003506414 A5 JP 2003506414A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- stated
- pharmaceutical composition
- bone marrow
- nhl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 description 22
- 210000001185 bone marrow Anatomy 0.000 description 20
- 238000001764 infiltration Methods 0.000 description 19
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 17
- 230000008595 infiltration Effects 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 10
- 238000000034 method Methods 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 230000002285 radioactive effect Effects 0.000 description 5
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 230000000779 depleting effect Effects 0.000 description 3
- 208000002008 AIDS-Related Lymphoma Diseases 0.000 description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 2
- 206010025312 Lymphoma AIDS related Diseases 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 2
- 208000000389 T-cell leukemia Diseases 0.000 description 2
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 2
- 206010042971 T-cell lymphoma Diseases 0.000 description 2
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 2
- 230000003325 follicular Effects 0.000 description 2
- 201000003444 follicular lymphoma Diseases 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 230000000527 lymphocytic effect Effects 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004980 dosimetry Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 231100000226 haematotoxicity Toxicity 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14828899P | 1999-08-11 | 1999-08-11 | |
| US60/148,288 | 1999-08-11 | ||
| US09/625,856 | 2000-07-26 | ||
| US09/625,856 US6451284B1 (en) | 1999-08-11 | 2000-07-26 | Clinical parameters for determining hematologic toxicity prior to radioimmunotheraphy |
| PCT/US2000/020733 WO2001010461A1 (en) | 1999-08-11 | 2000-07-31 | New clinical parameters for determining hematologic toxicity prior to radioimmunotherapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2003506414A JP2003506414A (ja) | 2003-02-18 |
| JP2003506414A5 true JP2003506414A5 (https=) | 2007-10-04 |
| JP4662672B2 JP4662672B2 (ja) | 2011-03-30 |
Family
ID=26845721
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001514977A Expired - Lifetime JP4662672B2 (ja) | 1999-08-11 | 2000-07-31 | 放射性免疫療法に先立つ血液学的毒性測定のための新規な臨床検査指標 |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US6451284B1 (https=) |
| EP (1) | EP1207904B1 (https=) |
| JP (1) | JP4662672B2 (https=) |
| CN (2) | CN1596985A (https=) |
| AT (1) | ATE387915T1 (https=) |
| AU (2) | AU780222B2 (https=) |
| CA (1) | CA2378584C (https=) |
| CY (1) | CY1108118T1 (https=) |
| DE (1) | DE60038239T2 (https=) |
| DK (1) | DK1207904T3 (https=) |
| ES (1) | ES2302698T3 (https=) |
| MX (1) | MXPA02001403A (https=) |
| MY (1) | MY135734A (https=) |
| NO (1) | NO329592B1 (https=) |
| PT (1) | PT1207904E (https=) |
| TW (1) | TWI317284B (https=) |
| WO (1) | WO2001010461A1 (https=) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000067796A1 (en) | 1999-05-07 | 2000-11-16 | Genentech, Inc. | Treatment of autoimmune diseases with antagonists which bind to b cell surface markers |
| AU784971B2 (en) * | 1999-08-11 | 2006-08-10 | Biogen Inc. | Treatment of patients having non-Hodgkins lymphoma with bone marrow involvement with anti-CD20 antibodies |
| US6451284B1 (en) * | 1999-08-11 | 2002-09-17 | Idec Pharmaceuticals Corporation | Clinical parameters for determining hematologic toxicity prior to radioimmunotheraphy |
| JP2004512262A (ja) | 2000-06-20 | 2004-04-22 | アイデック ファーマスーティカルズ コーポレイション | 非放射性抗ｃｄ２０抗体／放射標識抗ｃｄ２２抗体の組合せ |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| IL157946A0 (en) * | 2001-04-02 | 2004-03-28 | Genentech Inc | Combination therapy |
| TWI335821B (en) | 2002-12-16 | 2011-01-11 | Genentech Inc | Immunoglobulin variants and uses thereof |
| EP1613350B1 (en) | 2003-04-09 | 2009-03-18 | Genentech, Inc. | Therapy of autoimmune disease in a patient with an inadequate response to a tnf-alpha inhibitor |
| CN1802388B (zh) * | 2003-05-09 | 2011-01-05 | 杜克大学 | Cd20特异抗体及使用它们的方法 |
| JP2007526220A (ja) | 2003-06-05 | 2007-09-13 | ジェネンテック・インコーポレーテッド | Ｂ細胞疾患の併用療法 |
| US9296820B2 (en) | 2003-11-05 | 2016-03-29 | Roche Glycart Ag | Polynucleotides encoding anti-CD20 antigen binding molecules with increased Fc receptor binding affinity and effector function |
| JP5139058B2 (ja) * | 2004-06-02 | 2013-02-06 | シドニー キンメル キャンサー センター | 新形成または新生脈管構造の検出、画像化および処置のための血管標的 |
| AU2005249566B2 (en) | 2004-06-04 | 2010-11-11 | Genentech, Inc. | Method for treating multiple sclerosis |
| ZA200709956B (en) | 2005-05-20 | 2009-02-25 | Genentech Inc | Pretreatment of a biological sample from an autoimmune disease subject |
| RU2423381C2 (ru) | 2005-07-25 | 2011-07-10 | Трабьон Фармасьютикалз, Инк. | Снижение количества в-клеток с использованием cd37-специфических и cd20-специфических связывающих молекул |
| RU2421242C2 (ru) | 2005-07-25 | 2011-06-20 | Трабьон Фармасьютикалз, Инк. | Применение однократной дозы cd20-специфических связывающих молекул |
| MY149159A (en) | 2005-11-15 | 2013-07-31 | Hoffmann La Roche | Method for treating joint damage |
| ES2618543T3 (es) | 2005-11-23 | 2017-06-21 | Genentech, Inc. | Métodos y composiciones relacionados con ensayos de linfocitos B |
| NZ573646A (en) | 2006-06-12 | 2012-04-27 | Wyeth Llc | Single-chain multivalent binding proteins with effector function |
| RU2495882C2 (ru) * | 2006-09-08 | 2013-10-20 | Медиммун, Ллк. | Гуманизированные антитела к cd19 и их применение для лечения онкологического, связанного с трансплантацией и аутоиммунного заболевания |
| KR102055873B1 (ko) | 2007-07-09 | 2019-12-13 | 제넨테크, 인크. | 폴리펩티드의 재조합 생산 동안의 디술피드 결합 환원의 방지 |
| HUE030134T2 (en) | 2007-10-16 | 2017-04-28 | Zymogenetics Inc | Combination of transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) and anti-CD20 agents for the treatment of autoimmune diseases |
| US7914785B2 (en) | 2008-01-02 | 2011-03-29 | Bergen Teknologieverforing As | B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome |
| EP2077281A1 (en) | 2008-01-02 | 2009-07-08 | Bergen Teknologioverforing AS | Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome |
| RU2531754C2 (ru) | 2008-04-11 | 2014-10-27 | ЭМЕРДЖЕНТ ПРОДАКТ ДИВЕЛОПМЕНТ СИЭТЛ,ЭлЭлСи,US | Связывающееся с cd37 иммунотерапевтическое средство и его комбинация с бифункциональным химиотерапевтическим средством |
| AR073295A1 (es) | 2008-09-16 | 2010-10-28 | Genentech Inc | Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion. |
| WO2010075249A2 (en) | 2008-12-22 | 2010-07-01 | Genentech, Inc. | A method for treating rheumatoid arthritis with b-cell antagonists |
| HRP20200768T4 (hr) | 2009-08-11 | 2025-03-28 | F. Hoffmann - La Roche Ag | Proizvodnja proteina u mediju za uzgoj stanica bez glutamina |
| KR20130009760A (ko) | 2010-02-10 | 2013-01-23 | 이뮤노젠 아이엔씨 | Ｃｄ２０ 항체 및 이의 용도 |
| CN106030343B (zh) | 2013-12-17 | 2019-11-01 | 阿兰蒂克微科学股份有限公司 | 包括无透镜成像系统的剂量计 |
| EP3303373B1 (en) | 2015-05-30 | 2020-04-08 | Molecular Templates, Inc. | De-immunized, shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same |
| HUE057952T2 (hu) | 2015-06-24 | 2022-06-28 | Hoffmann La Roche | Anti-transzferrin receptor antitestek testreszabott affinitással |
| WO2017053469A2 (en) | 2015-09-21 | 2017-03-30 | Aptevo Research And Development Llc | Cd3 binding polypeptides |
| TWI873952B (zh) | 2015-10-02 | 2025-02-21 | 瑞士商赫孚孟拉羅股份公司 | 雙特異性抗‐人類cd20/人類轉鐵蛋白受體抗體及使用方法 |
| AR106189A1 (es) | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO |
| EP3714937A1 (en) * | 2019-03-28 | 2020-09-30 | Koninklijke Philips N.V. | Determining hematologic toxicity risk following radiotherapy |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5242679A (en) * | 1985-01-14 | 1993-09-07 | Neorx Corporation | Metal radionuclide labeled proteins for diagnosis and therapy |
| US5099069A (en) | 1986-09-05 | 1992-03-24 | Gansow Otto A | Backbone polysubstituted chelates for forming a metal chelate-protein conjugate |
| US5246692A (en) | 1986-09-05 | 1993-09-21 | The United States Of America As Represented By The Secretary Of Health And Human Services | Backbone polysubstituted chelates for forming a metal chelate-protein conjugate |
| US5591632A (en) * | 1987-03-02 | 1997-01-07 | Beth Israel Hospital | Recombinant BCG |
| US5124471A (en) | 1990-03-26 | 1992-06-23 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Bifunctional dtpa-type ligand |
| WO1992007466A1 (en) | 1990-11-05 | 1992-05-14 | Bristol-Myers Squibb Company | Synergistic therapy with combinations of anti-tumor antibodies and biologically active agents |
| US7744877B2 (en) * | 1992-11-13 | 2010-06-29 | Biogen Idec Inc. | Expression and use of anti-CD20 Antibodies |
| US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| DK0752248T3 (da) | 1992-11-13 | 2000-11-13 | Idec Pharma Corp | Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig |
| US5595721A (en) | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
| DE69534530T2 (de) | 1994-08-12 | 2006-07-06 | Immunomedics, Inc. | Für b-zell-lymphom und leukämiezellen spezifische immunkonjugate und humane antikörper |
| US6113898A (en) | 1995-06-07 | 2000-09-05 | Idec Pharmaceuticals Corporation | Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies |
| US5843436A (en) * | 1996-04-22 | 1998-12-01 | The Trustees Of Columbia University, In The City Of New York | Method of preventing and treating bacterial infection of sutures and prosthetic devices, and promoting ingress of leukocytes into tumor foci |
| US6306393B1 (en) | 1997-03-24 | 2001-10-23 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
| US6183744B1 (en) | 1997-03-24 | 2001-02-06 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
| PT1974747E (pt) * | 1998-08-11 | 2012-09-05 | Biogen Idec Inc | Terapias de combinação para linfomas de células b compreendendo a administração de anticorpo anti-cd20 |
| US6224866B1 (en) | 1998-10-07 | 2001-05-01 | Biocrystal Ltd. | Immunotherapy of B cell involvement in progression of solid, nonlymphoid tumors |
| WO2000067796A1 (en) | 1999-05-07 | 2000-11-16 | Genentech, Inc. | Treatment of autoimmune diseases with antagonists which bind to b cell surface markers |
| DE60042785D1 (de) | 1999-06-09 | 2009-10-01 | Immunomedics Inc | Immuntherapie von autoimmunerkrankungen durch die verwendung von b-zell spezifischen antikörpern |
| US6451284B1 (en) | 1999-08-11 | 2002-09-17 | Idec Pharmaceuticals Corporation | Clinical parameters for determining hematologic toxicity prior to radioimmunotheraphy |
| US20020006404A1 (en) | 1999-11-08 | 2002-01-17 | Idec Pharmaceuticals Corporation | Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications |
| JP2004508420A (ja) | 2000-09-18 | 2004-03-18 | アイデック ファーマスーティカルズ コーポレイション | Ｂ細胞枯渇抗体／免疫調節性抗体の組合せを用いて自己免疫疾患を治療するための併用療法 |
-
2000
- 2000-07-26 US US09/625,856 patent/US6451284B1/en not_active Expired - Lifetime
- 2000-07-31 CN CNA2004100590274A patent/CN1596985A/zh active Pending
- 2000-07-31 ES ES00959150T patent/ES2302698T3/es not_active Expired - Lifetime
- 2000-07-31 CA CA2378584A patent/CA2378584C/en not_active Expired - Lifetime
- 2000-07-31 AT AT00959150T patent/ATE387915T1/de active
- 2000-07-31 PT PT00959150T patent/PT1207904E/pt unknown
- 2000-07-31 WO PCT/US2000/020733 patent/WO2001010461A1/en not_active Ceased
- 2000-07-31 JP JP2001514977A patent/JP4662672B2/ja not_active Expired - Lifetime
- 2000-07-31 CN CNB008124426A patent/CN100540053C/zh not_active Expired - Lifetime
- 2000-07-31 EP EP00959150A patent/EP1207904B1/en not_active Expired - Lifetime
- 2000-07-31 AU AU70521/00A patent/AU780222B2/en not_active Expired
- 2000-07-31 DK DK00959150T patent/DK1207904T3/da active
- 2000-07-31 MX MXPA02001403A patent/MXPA02001403A/es active IP Right Grant
- 2000-07-31 DE DE60038239T patent/DE60038239T2/de not_active Expired - Lifetime
- 2000-08-04 MY MYPI20003577A patent/MY135734A/en unknown
- 2000-08-11 TW TW089116242A patent/TWI317284B/zh not_active IP Right Cessation
-
2002
- 2002-02-08 NO NO20020637A patent/NO329592B1/no not_active IP Right Cessation
- 2002-07-16 US US10/195,426 patent/US7195750B2/en not_active Expired - Lifetime
-
2005
- 2005-06-10 AU AU2005202560A patent/AU2005202560B2/en not_active Expired
-
2007
- 2007-02-27 US US11/679,687 patent/US20070148714A1/en not_active Abandoned
-
2008
- 2008-06-03 CY CY20081100584T patent/CY1108118T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003506414A5 (https=) | ||
| DE60038239T2 (de) | Neue klinische parameter zur bestimmung einer hämatologischen toxizität vor einer strahlenimmuntherapie | |
| Davis et al. | The radioisotope contributes significantly to the activity of radioimmunotherapy | |
| Lindén et al. | Dose-fractionated radioimmunotherapy in non-Hodgkin's lymphoma using DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab | |
| JP2003513012A5 (https=) | ||
| Burke et al. | Radioimmunotherapy for acute leukemia | |
| JP2003506413A (ja) | 中間および高グレードの非ホジキンリンパ腫の抗−ｃｄ２０抗体による治療 | |
| JP2004512262A5 (https=) | ||
| AU7626000A (en) | Treatment of patients having non-hodgkins lymphoma with bone marrow involvement with anti-cd20 antibodies | |
| Tuscano et al. | Anti-CD22 ligand-blocking antibody HB22. 7 has independent lymphomacidal properties and augments the efficacy of90Y-DOTA-peptide-Lym-1 in lymphoma xenografts | |
| Borghaei et al. | Safety and efficacy of radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin) | |
| Witzig | Efficacy and safety of 90Y ibritumomab tiuxetan (Zevalin) radioimmunotherapy for non-Hodgkin’s lymphoma | |
| Iagaru et al. | 131I-Tositumomab (Bexxar®) vs. 90Y-Ibritumomab (Zevalin®) therapy of low-grade refractory/relapsed Non-Hodgkin Lymphoma | |
| Illidge et al. | Radioimmunotherapy in follicular lymphoma | |
| Michel et al. | 177Lu-antibody conjugates for single-cell kill of B-lymphoma cells in vitro and for therapy of micrometastases in vivo | |
| Buchegger et al. | Long-term complete responses after 131I-tositumomab therapy for relapsed or refractory indolent non-Hodgkin's lymphoma | |
| Torres-García et al. | Biokinetics and dosimetry of 188Re-anti-CD20 in patients with non-Hodgkin's lymphoma: preliminary experience | |
| Emmanouilides | Radioimmunotherapy for non-Hodgkin’s lymphoma | |
| Leonard et al. | Comparative Physical and Pharmacologic Characteristics of Iodine-131 and Yttrium-90: Implications for Radioimmunotherapy for Patients with Non-Hodgkin's Lymphoma: HEMATOLOGY | |
| William et al. | I-131 tositumomab | |
| White | Radioimmunotherapy in non-Hodgkin's lymphoma: focus on 90Y-ibritumomab tiuxetan (Zevalin®). | |
| Bailly et al. | Radioimmunotherapy of lymphomas | |
| Meredith et al. | Clinical development of radioimmunotherapy for B-cell non-Hodgkin’s lymphoma | |
| Petryk et al. | Hematologic malignancies | |
| Jurcic | Targeted alpha-particle immunotherapy with bismuth-213 and actinium-225 for acute myeloid leukemia |